Caley Denevers
Family · Las Vegas, NMNPI 1093332587
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 159 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 39.0% of the total. 2025 is the largest year on record at $1,247, more than ten times the $122 reported in 2021. Among family clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 159 payments — averaging $21.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$425
- Novo Nordisk$404
- Viatris Specialty LLC$232
- Lilly USA, LLC$224
- AstraZeneca$197
- plus $587 from 13 others
What the payments were for
- Food & beverage$3,392100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 64 | $1,325 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $425 |
| Novo Nordisk | 20 | $404 |
| Viatris Specialty LLC | 7 | $232 |
| Lilly USA, LLC | 7 | $224 |
| AstraZeneca | 13 | $197 |
| Exact Sciences | 5 | $99 |
| GSK | 6 | $94 |
| Mylan Specialty L.p. | 5 | $92 |
| Pfizer | 4 | $76 |
| Astellas Pharma US Inc | 2 | $49 |
| Lundbeck LLC | 2 | $41 |
| Nevro Corp. | 1 | $31 |
| Inspire Medical Systems, Inc. | 1 | $28 |
| Coopersurgical, Inc. | 1 | $20 |
| Angiodynamics, Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,392 in reported general payments places this provider in the 90th percentile of 1,080 family providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 54 | $64,787 |
| TrulicityDulaglutide | 37 | $52,419 |
| RybelsusSemaglutide | 17 | $39,265 |
| VraylarCariprazine Hcl | 24 | $33,534 |
| EliquisApixaban | 15 | $26,648 |
| Spiriva RespimatTiotropium Bromide | 38 | $24,476 |
| XareltoRivaroxaban | 14 | $22,021 |
| JardianceEmpagliflozin | 16 | $20,141 |
| MounjaroTirzepatide | 17 | $18,727 |
| FarxigaDapagliflozin Propanediol | 13 | $18,623 |
| AdderallDextroamphetamine/Amphetamine | 11 | $7,601 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $3,996 |
| BreynaBudesonide/Formoterol Fumarate | 18 | $3,636 |
| Pregabalin | 50 | $3,121 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 112 | $2,840 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $404 | $104,05271 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $224 | $71,14654 claims |
| AbbVieVraylar, Synthroid | $1,325 | $34,22936 claims |
| PfizerEliquis | $76 | $26,64815 claims |
| AstraZenecaFarxiga, Symbicort | $197 | $22,61931 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,080 family providers in New Mexico.
Other family in Las Vegas
- David SeiterFarmington$194K
- Carol HollandRoswell$81K
- Barbara FranklinAlbuquerque$28K
- Laurie CrockettArtesia$19K
- Kaylene CribbsFarmington$17K
- Melanie DuranAlbuquerque$15K
- Irasema LlewellynAlbuquerque$14K
- Jamie LujanLas Cruces$14K
- Katie BoylanRio Rancho$11K
- Charles GallegosAlbuquerque$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.